PRODUCT DEVELOPMENT, LICENCE AND COMMERCIALIZATION AGREEMENTLicence and Commercialization Agreement • December 16th, 2016 • Stocosil Inc. • Pharmaceutical preparations
This Product Development, Licence and Commercialization Agreement (“Agreement”) is made and entered into as of February 27th, 2015 by and between Daewoong Pharmaceuticals Co. Ltd. a company incorporated under the laws of South Korea and having its registered office at 163-3, Samsung-Dong, Kangnam-Gu, Seoul, Korea (“DAEWOONG”) and Autotelic, LLC and Autotelic, Inc., and Stocosil Inc. (“STOCOSIL”) companies incorporated under the laws of Delaware, having its registered office at 17870 Castleton Street, Ste. 250, City of Industry, CA 91748, USA. (“STOCOSIL”).
ContractLicence and Commercialization Agreement • May 5th, 2020
EX1A-6 MAT CTRCT 8 ex6-1.htm PRODUCT DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT Exhibit 6.1 PRODUCT DEVELOPMENT, LICENCE AND COMMERCIALIZATION AGREEMENT This Product Development, Licence and Commercialization Agreement (“Agreement”) is made and entered into as of February 27th, 2015 by and between Daewoong Pharmaceuticals Co. Ltd. a company incorporated under the laws of South Korea and having its registered office at 163-3, Samsung-Dong, Kangnam-Gu, Seoul, Korea (“DAEWOONG”) and Autotelic, LLC and Autotelic, Inc., and Stocosil Inc. (“STOCOSIL”) companies incorporated under the laws of Delaware, having its registered office at 17870 Castleton Street, Ste. 250, City of Industry, CA 91748, USA. (“STOCOSIL”). STOCOSIL will be the main party to this Agreeemnt, and Autotelic, LLC together with Autotelic, Inc., (“AUTOTELIC”) will be the secondary parties to this Agreement and the “Sponsor” (to be defined below in the Definition Clause) of STOCOSIL. As the Sponsor of STOCOSIL, AUTOT
